Relay Therapeutics is trading 4.94% down at $16.90 on November 5, 2026, with broad market weakness the likelier backdrop; no company-specific negative catalyst was identified. - Its third-quarter report showed a loss of $81.7 million, with cash expected to fund operations into 2029. - The Nasdaq was down 3.23% and the S&P 500 down 1.86%. - Biotech was reportedly stronger, so the move is not clearly tracking its sector.